RESEARCH ARTICLE

Characteristics and outcomes in children with undifferentiated embryonal sarcoma of the liver: A report from the National Cancer Database

Yan Shi¹,²,³ | Yesenia Rojas¹,²,³ | Wei Zhang⁴ | Elizabeth A. Beierle⁵ | John J. Doski⁶ | Melanie Goldfarb⁷ | Adam B. Goldin⁸ | Kenneth W. Gow⁸ | Monica Langer⁹ | Rebecka L. Meyers¹⁰ | Jed G. Nuchtern¹,²,³ | Sanjeev A. Vasudevan¹,²,³

¹ Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
² Texas Children’s Department of Surgery, Texas Children’s Liver Tumor Center, Baylor College of Medicine, Houston, Texas
³ Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas
⁴ Outcomes & Impact Service, Department of Surgery, Texas Children’s Hospital, Houston, Texas
⁵ Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Alabama
⁶ Department of Surgery, Methodist Children’s Hospital of South Texas, University of Texas Health Science Center - San Antonio, San Antonio, Texas
⁷ Department of Surgery, John Wayne Cancer Institute at Providence St. Johns Health Center, Santa Monica, California
⁸ Division of Pediatric General and Thoracic Surgery, Seattle Children’s Hospital, Department of Surgery, University of Washington, Seattle, Washington
⁹ Department of Surgery, Maine Children’s Cancer Program, Tufts University, Portland, Maine
¹⁰ Division of Pediatric Surgery, Primary Children’s Hospital, University of Utah, Salt Lake City, Utah

Correspondence
Sanjeev A. Vasudevan, Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey and Texas Children’s Departments of Surgery, Texas Children’s Liver Tumor Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, 6701 Fannin, Suite 1210, Houston, TX 77030.
Email: sanjeev@bcm.edu

Grant sponsor: Texas Children’s Department of Surgery SEED Grant (SAV) Grant sponsor: Baylor College of Medicine Michael E. DeBakey Department of Surgery Faculty Award (SAV) American College of Surgeons and the American Cancer Society are the sponsors of the database which was used. They did not directly fund this study.

Abstract

Objective: To examine patient characteristics and outcomes in children with undifferentiated embryonal sarcoma of the liver (UESL) using a multi-institutional database.

Summary Background Data: UESL is a rare disease (incidence is one per million). Therefore, the current literature is mostly limited to small case series.

Methods: The National Cancer Database was queried for primary UESL diagnosed between 1998 and 2012.

Results: A total of 103 patients (<18 years) were identified. The 5-year overall survival of the entire group was 86%. The best outcomes were seen in children who had tumors smaller than 15 cm and were able to undergo surgical resection with or without chemotherapy. Margin status did not appear to significantly affect survival. The most common type of resection was hemihepatectomy (37%), followed by sectionectomy (10%) and trisectionectomy (10%). Orthotopic liver transplant was performed in 10 children, all of whom survived to 5 years.

Conclusion: Surgical resection with or without chemotherapy should be the mainstay of treatment in children with UESL, and is associated with very favorable outcomes. Negative surgical margins were not associated with improved survival. Orthotopic liver transplantation may be a viable method of attaining local control in tumors, which would otherwise be unresectable.

Abbreviations: CoC, Commission on Cancer; COG, Children’s Oncology Group; IQR, interquartile range; NCDB, National Cancer Database; OLT, Orthotopic liver transplant; OS, overall survival; PRETEXT, Pretreatment Extent of Disease; PUF, Participant User File; UESL, undifferentiated embryonal sarcoma of the liver

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2016 The Authors. Pediatric Blood & Cancer Published by Wiley Periodicals, Inc.
INTRODUCTION

Undifferentiated embryonal sarcoma of the liver (UESL) is a rare neoplasm that accounts for 9–15% of pediatric liver malignancies and is the third most common malignant liver tumor in children, following hepatoblastoma and hepatocellular carcinoma. The peak incidence of UESL is between 6 and 10 years of age. Some series report a female predominance, while others report an even-gender distribution. Tumor sizes are between 10 and 30 cm. UESL arises more commonly from the right lobe of the liver and presents clinically with nonspecific symptoms of abdominal pain, fever, nausea, and anorexia. Imaging demonstrates cystic and solid components, and serum a-fetoprotein is usually normal. Historically, treatment was limited to radical surgical resection, with chemotherapy and radiation used infrequently, leading to a dismal prognosis with a median overall survival (OS) of less than 1 year. Mortality was primarily from recurrent and metastatic disease. More recently, aggressive treatment regimens that combine chemotherapy and surgical resection have improved survival substantially.

Due to its low incidence, much of the literature regarding UESL is from small case series or case reports. The largest series from 1978 had 31 patients, and no adult series has more than two cases. Therefore, few data exist to help guide therapy and counsel patients and their families. Previously reported factors associated with worse OS are local recurrence, tumor rupture, and metastatic disease. Outside of meta-analyses, there are no large retrospective single-source analyses of UESL characteristics and prognostic factors. The National Cancer Database (NCDB) is a U.S.-based, nationwide multi-institutional database that is jointly managed by the American College of Surgeon’s Commission on Cancer (CoC) and the American Cancer Society. It captures approximately 70% of all newly diagnosed cases of cancer in the United States from over 1,500 participating CoC programs. Because of its large scale, the NCDB provides a unique opportunity to examine rare pathologies such as this one, where the previous literature is limited. This study aims to outline the patient and disease characteristics, as well as identify factors that correlate with OS in children with UESL using the largest dataset to date from the NCDB.

METHODS

Data source and study population

This dataset was obtained from the NCDB Participant User File (PUF) for liver neoplasms. The PUF files are deidentified for patient and facility-specific information in accordance with the requirements of the Health Insurance Portability and Accountability Act. This study was limited to patients <18 years with primary UESL, who were diagnosed between 1998 and 2012. The dataset was queried using tumor histology codes from the International Classification of Disease for Oncology 3rd Edition (ICD-O-3): code 8805 for undifferentiated sarcoma and code 8991 for embryonal sarcoma.

Variables

The variables that were chosen to be included in the analysis were limited to those with fewer than 20% incomplete data and can be found in Table 1. Income and education levels were derived from the 2008 U.S. Census data based on the patients’ reported zip code of residence. The variable “Treatment Modality” refers to whether patients had no treatment, chemotherapy only, surgical resection only, or combined therapy. Combined therapy refers to the combination of chemotherapy and surgical resection of any kind. Radiation therapy was not included in this variable, as a small minority of patients had radiation therapy as part of their treatment course.

Statistical methods

Continuous variables are reported as a mean or median, with the corresponding absolute range or interquartile range (IQR), respectively. Categorical variables are reported as frequencies with the corresponding percentages.

Kaplan–Meier analyses of OS were conducted for each variable; differences were tested with the log-rank test, and 5-year OS was calculated from mortality tables. Univariate analysis was performed using a Cox proportional hazard model. For multivariate analysis, potential confounding covariates with a P-value of <0.20 on univariate analysis were entered into a Cox proportional hazard regression model. Since the variable “treatment modality” is inclusive of the “resection” and “chemotherapy” variables, only “treatment modality” was used in the multivariate model. The optimal cutpoint for tumor size was determined using the minimum P-value approach. The statistical analysis was performed using STATA 13.0 (StataCorp LP, College Station, TX) and SAS 9.3 (SAS Institute, Inc., Cary, NC).

RESULTS

Study population and demographic variables

A total of 103 children (age <18 years) with a primary diagnosis of UESL between 1998 and 2012 were identified in the NCDB registry. Survival data were available for 100 of these children.

Demographics, tumor extent, and treatment

The demographic, tumor, and treatment characteristics are summarized in Table 1. Children with UESL had a median age of 9 years
### TABLE 1 (Continued)

| N = 103, n (% of N) |
|---------------------|
| Resection type       |
| No surgery          | 13 (13)  |
| Local destruction   | 0 (0)    |
| Sectionectomy       | 29 (28)  |
| Hemihpatectomy      | 38 (37)  |
| Trisectionectomy    | 10 (10)  |
| Orthotopic liver transplant | 10 (10) |
| Surgery, NOS         | 3 (3)    |

NOS, not otherwise specified; IQR, interquartile range.

*(Data missing in 36 of 103 records.)*

(IQR: 5–12 years) and no gender predilection. The median size was 14 cm (IQR: 11–16 cm). Lymph nodes were sampled in only 22 of 89 (25%) patients who underwent a surgical operation. Of these, lymph node involvement was seen in 1 of 22 (4.5%) nodes sampled. Combined therapy was utilized in a great majority of cases (82%). Eighty-nine (86%) patients underwent resection, while 13 (13%) did not. Among the patients who had surgery, hemihpatectomy (37%) and sectionectomy (28%) were the most commonly utilized methods of resection. Almost all patients were treated with chemotherapy (90%), while only 15 (15%) had radiation therapy. All patients who had radiation also underwent combined chemotherapy and surgical resection. Metastases were present in 15% of patients. Among patients who did not have surgery, metastatic disease was present in three (38%) patients compared to seven (13%) patients who did have surgery. Ten orthotopic liver transplants (OLT) were also performed, and all these patients survived to 5 years. A margin-free resection was achieved in 51 of 89 (57%) children who underwent resection, and all children with positive margins received chemotherapy.

### 3.3 Survival analysis

#### 3.3.1 Univariate analysis

Table 2 shows the results of the univariate survival analysis. The 5-year OS for the entire patient population was 86%. In children who underwent combined therapy, the 5-year OS was 92%. Factors associated with better OS were combined therapy (*P* < 0.01), sectionectomy (*P* = 0.03), and hemihpatectomy (*P* = 0.001). Unknown tumor size is likely only significant as it comprises a larger proportion of patients who did not have surgery. Socioeconomic factors such as gender, race, ethnicity, insurance type, and income did not have an impact on survival. Chemotherapy alone, radiation, and surgical margins were not significant prognostic factors. All the patients who had radiation treatment also had combined therapy. There was no significant difference in survival within the combined therapy group with the addition of radiation treatment (*P* = 0.26). Radiation was also not used exclusively for patients with positive margins. Radiation was given to six patients with negative margins and seven patients with positive margins, two patients had margins that were unknown. The OS of the five patients who had surgical resection alone was 100%. There was one sectionectomy, two hemihpatectomies, one trisectionectomy, and one OLT. All these patients had negative margins.
|                              | N = 100 |     |    |     |     |
|------------------------------|---------|-----|----|-----|-----|
|                              | HR     | 95% CI | P-value | 5-year OS (%) |
| Gender                       |         |       | 0.16 | 80  |
| Male                         | REF    |       | -    | -   |
| Female                       | 0.43   | 0.13–1.4 | -    | 92  |
| Race                         |         |       | 0.63 | 87  |
| Caucasian                    | REF    |       | -    | -   |
| African American             | 0.60   | 0.08–4.7 | -    | 89  |
| Other                        | 1.83   | 0.24–14 | -    | 67  |
| Unknown                      | -      | -      | -    | -   |
| Spanish origin               |         |       | 0.32 | 92  |
| Non-Hispanic                 | REF    |       | -    | -   |
| Hispanic                     | 0.47   | 0.10–2.1 | -    | 92  |
| Unknown                      | -      | -      | -    | -   |
| Insurance status             |         |       | 0.76 | 88  |
| Public                       | REF    |       | -    | -   |
| Private                      | 0.83   | 0.25–2.7 | -    | 88  |
| None                         | 7.5    | 0.87–66 | -    | 50  |
| Unknown                      | 0.28   | 0.12–4.6 | -    | 75  |
| Income                       |         |       | 0.35 | 85  |
| <$63,000                     | REF    |       | -    | -   |
| $63,000                      | 0.22   | 0.03–1.7 | -    | 96  |
| Unknown                      | -      | -      | -    | -   |
| Tumor size                   |         |       | 0.02 | 92  |
| <15 cm                       | REF    |       | -    | -   |
| ≥15 cm                       | 5.1    | 1.4–19 | -    | 69  |
| Unknown                      | 1.9    | 0.49–7.8 | -    | -   |
| Radiation therapy            |         |       | 0.775| 50  |
| No                           | REF    |       | -    | -   |
| Yes                          | 1.1    | 0.24–4.9 | -    | 84  |
| Unknown                      | -      | -      | -    | -   |
| Margins                      |         |       | 0.11 | 83  |
| Negative                     | REF    |       | -    | -   |
| Positive                     | 4.4    | 0.73–26 | -    | 95  |
| Unknown                      | 1.3    | 0.11–14 | -    | -   |
| Treatment modality           |         |       | 0.01 | 92  |
| Chemotherapy only            | REF    |       | -    | -   |
| No treatment                 | 1.27   | 0.25–6.6 | -    | 50  |
| Surgery only                 | -      | -      | -    | -   |
| Combined therapy             | 0.10   | 0.03–0.33 | -    | -   |
| Unknown                      | -      | -      | -    | -   |
| Chemotherapy                 |         |       | 0.29 | 87  |
| No                           | REF    |       | -    | -   |
| Yes                          | 0.44   | 0.10–2.0 | -    | 87  |
| Unknown                      | -      | -      | -    | -   |
| Resection type               |         |       | 0.01 | 90  |
| No surgery                   | REF    |       | -    | -   |
| Local destruction            | -      | -      | -    | -   |
| Sectionectomy                | 0.09   | 0.02–0.45 | -    | 93  |
| Hemihepatectomy              | 0.10   | 0.03–0.39 | -    | -   |
| Trisectionectomy             | 0.14   | 0.02–1.1 | -    | -   |
| Orthotopic liver transplant  | -      | -      | -    | -   |
| Surgery, NOS                 | -      | -      | -    | -   |

REF, reference variable; NOS, not otherwise specified; HR, hazard ratio; CI, confidence interval; ‘-’, insufficient cases for analysis. P values <0.05 are shown in bold.
**TABLE 3** Multivariate Cox proportional hazards regression

|                      | HR     | 95% CI     | P-value |
|----------------------|--------|------------|---------|
| **Gender**           |        |            |         |
| Male                 | REF    |            |         |
| Female               | 0.49   | 0.13–1.9   | 0.30    |
| **Insurance status** |        |            |         |
| Public               | REF    |            |         |
| Private              | 1.4    | 0.38–5.1   | 0.61    |
| None                 | 3.8    | 0.23–62    | 0.36    |
| Unknown              | 4.3    | 0.31–61    | 0.28    |
| **Income**           |        |            |         |
| <$63,000             | REF    |            |         |
| ≥$63,000             | 0.47   | 0.06–4.0   | 0.50    |
| Unknown              | –      | –          | –       |
| **Tumor size**       |        |            |         |
| <15 cm               | REF    |            |         |
| ≥15 cm               | 8.1    | 1.3–48     | 0.02    |
| Unknown              | 4.7    | 1.0–22     | 0.05    |
| **Treatment modality**|       |            |         |
| Chemotherapy only    | REF    |            |         |
| No treatment         | 2.2    | 0.25–19    | 0.49    |
| Surgery only         | –      | –          | –       |
| Combined therapy     | 0.03   | 0.004–0.27 | <0.01   |
| Unknown              | –      | –          | –       |
| **Margins of resection** |    |            |         |
| Negative             | REF    |            |         |
| Positive             | 5.7    | 0.96–37    | 0.07    |
| Not applicable       | –      | –          | –       |
| Unknown              | 1.3    | 0.10–17    | 0.86    |

REF, reference variable; HR, hazard ratio; CI, confidence interval; “–”, insufficient cases for analysis. P values <0.05 are shown in bold.

OS was 91% in patients who did not have metastatic disease (N = 51) and 70% in patients who did (N = 10). The OS for patients who had metastatic disease and underwent combined therapy was 86% (N = 7). It is important to note that the presence of metastatic disease was only recorded in 64 of 103 records.

The OS of the pediatric transplant patients was 100% (N = 10). Nine of 10 children had chemotherapy with OLT. The mean tumor size of transplant patients was 13.7 cm (1.4–24 cm).

### 3.3.2 Multivariate analysis

Table 3 shows the results of the Cox model multivariate analysis for OS. The covariates used in the model were gender, insurance, income, tumor size, tumor margins, and treatment modality. The ending sample size in this model was 100.

Tumor size ≥15 cm (hazard ratio [HR] = 8.1, 95% CI = 1.3–48; P = 0.02) and combined therapy (HR = 0.03, 95% CI = 0.004 – 0.27; P < 0.01) were the only two independent prognostic factors.

### 4 DISCUSSION

The purpose of this study was to broadly characterize patient and disease characteristics and identify factors associated with prognosis in UESL using the largest dataset of patients to date from the NCDB. There is currently a paucity of data related to demographics, tumor characteristics, prognostic indicators, and optimal treatment in patients with UESL. This analysis demonstrates that surgical resection alone, and combined therapy were associated with the best prognosis.

In prior decades, prognosis for UESL was considered poor; the long-term disease-free survival rate was less than 37%. However, these data were from an era that preceded the widespread use of combined therapy as the preferred treatment. Since then, the long-term survival rate of UESL patients has steadily improved (Table 4) and is currently reported to be >70%. Some of the first cases of long-term survivors treated with combination chemotherapy and surgery were described in the late 1980s. Newman et al. reported long-term survival in two of four patients. Urban et al. then reported a series of four survivors, who were followed for 22–79 months. The only prospective study of UESL treatment outcomes was reported by the Italian and German Soft Tissue Sarcoma Cooperative Group. From 1979 to 1996, 17 patients with UESL were identified and treated with the current regimen for pediatric rhabdomyosarcoma, and/or surgical resection, when appropriate. The authors reported following up on 13 survivors for periods ranging from 14 to 240 months. Three patients died of their disease, two had local recurrence, and one was incompletely resected. The addition of chemotherapy to surgical management is now increasingly being employed and has been credited with increasing the OS for UESL. This analysis supports these prior, smaller case series, which suggested that surgical resection alone, as well as combined therapy, were positive predictors of survival.
As with other hepatic malignancies such as hepatoblastoma and hepatocellular carcinoma, complete surgical resection is currently the mainstay of therapy for UESL. A distinct survival difference is seen between patients who underwent resection and those who did not. A small subgroup of five patients underwent surgical resection alone. All these patients had negative resection margins. These patients also had a variable extent of hepatic resection that ranged from sectionectomy to trisectionectomy and OLT. This indicated that all these were not small localized tumors. In this small sample, children treated with surgical resection alone with negative margins and no nodal disease had 100% survival. Although no firm conclusions can be drawn from such a small sample size, these data still pose an interesting question that is worth examining should a larger dataset of these patients become available.

In cases in which hepatic lesions are deemed unresectable due to multifocality or proximity to vital structures, OLT is used to achieve local control. Successful use of OLT in the treatment of UESL has been reported in a few small case reports and series and more recently in an analysis of the United Network for Organ Sharing database. Among this dataset of 10 children who underwent OLT, 100% were alive at 5 years. The degree of success seen in this interesting, albeit limited amount of data suggest that OLT could be a valid method for achieving local control for UESL in children, and should be considered when confronted with unresectable lesions. However, this remains a small number of cases and further investigation is warranted.

The objective when treating most liver tumors is to achieve a resection with a negative margin. Surprisingly, positive margins were not found to be significant predictors of outcome in this dataset. Given the reportedly good response to chemotherapy, adjuvant chemotherapy may be sufficient to control or eliminate residual disease after resection in UESL. Future examination of resection margin status using a larger patient population may provide a more definitive answer as to its significance.

Metastases have been reported to occur in 5–13% of children. Successful treatment using surgical resection with chemotherapy has been reported. In this dataset, metastases were present in 15% of patients for whom the records were available, and all these patients received chemotherapy as part of their treatment. These data show that patients who have metastatic disease may have a reasonable chance at long-term survival with combined surgery and chemotherapy. However, this conclusion must be tempered by the few cases available and large proportion of missing data for this field.

Currently, there are no standard chemotherapy regimens designed specifically for UESL. Accordingly, regimens reported in the literature are varied, and protocols originally designed for the treatment of pediatric rhabdomyosarcoma or other soft tissue sarcomas are often

| Author, publication year | No. of patients | Age range, years | Gender (M/F) | Surgical excision Only | Combined therapy |
|--------------------------|----------------|-----------------|--------------|------------------------|-----------------|
|                          |                |                 |              | No. of patients | Follow-up, months | Alive | No. of patients | Follow-up, months | Alive |
| Techavichit et al., 2016 | 6              | 5–22            | 3/3          | 0              | –                | 5     | 10–133         | 4/5            |
| Cao et al., 2014         | 9              | 6–37            | 6/3          | 1              | 34               | 0/1   | 8              | 5–76           | 7/8             |
| Walther et al., 2014     | 6              | 7–13            | 4/2          | 1 (1 OLT)      | 84               | 1/1   | 5 (2 OLT)      | 12–48          | 5/5             |
| Plant et al., 2013       | 5              | 10–19           | 4/1          | 0              | –                | –     | 5 (1 OLT)      | 21–68          | 5/5             |
| Ismaili et al., 2013     | 10             | 4 months to 17  | 8/2          | 0              | –                | –     | 10 (1 OLT)     | 50–222         | 9/10            |
| Upadhyaya et al., 2010   | 11             | 4 months to 15  | –            | 1              | NR               | 1/1   | 10             | –              | 7/10            |
| Weitz et al., 2007       | 5              | –               | –            | –              | –                | –     | –              | –              | d               |
| Bisogno et al., 2002     | 17             | 4 months to 16  | 10/7         | 1              | NR               | 0/1   | 15             | 14–240         | 12/15           |
| Kim et al., 2002         | 6              | 7–13            | 4/2          | 0              | –                | 6     | 22–108         | 5/6            |
| Webber et al., 1999      | 7              | 2–12            | 4/3          | 0              | –                | 7     | 6–150          | 4/7            |
| Urban et al., 1993       | 4              | 6–13            | 0/4          | 0              | –                | 4     | 22–79          | 4/4            |
| Walker et al., 1992      | 4              | 7–29            | 2/2          | 2              | 18–240           | 2/2   | 2              | 13–30          | 1/2             |
| Lack et al., 1991        | 16             | 2–21            | 10/6         | 7              | 4–12             | 0/7   | 9              | 4–60           | 3/9             |
| Leuschner et al., 1990   | 9              | 4–20            | 5/4          | 5              | 3–24             | 2/4   | 3              | 15–59          | 3/3             |
| Newman et al., 1989      | 4              | 5–13            | 2/2          | 0              | –                | –     | 4              | –              | 2/4             |
| Horowitz et al., 1987    | 5              | 4–16            | 4/1          | 1              | 6                | 0/1   | 4              | 12–58          | 2/4             |

NR, not reported; OLT, orthotopic liver transplant.

* One patient underwent chemotherapy only. The deceased patient from the combined therapy group had an incomplete resection.

† This patient underwent OLT without adjuvant chemotherapy due to local recurrence after prior resection with neoadjuvant and adjuvant chemotherapy.

‡ The deceased patient was initially diagnosed with hepatoblastoma and died 4 months posttransplant of postoperative complications.

§ All patients with embryonal sarcomas of the liver underwent surgical resection with negative margins, however the use of chemotherapy could not be ascertained. The overall survival of UESL patients in this study was 80% (4/5).

¶ Postsurgical death. The patient also had chemotherapy alone and died 1.8 years after diagnosis.

∥ One patient died of unrelated trauma.

§ One patient had no outcome reported.

---

**TABLE 4** Published reports of UESL (N > 3) from 1987 to 2014. Follow-up and outcome of patients who had surgical resection only, as well as combined therapy, are outlined.
The effectiveness of radiation therapy to prevent recurrence and improve survival in UESL is unknown. In a few cases, radiation therapy has been used in the postoperative setting to prevent recurrence in the tumor bed. Also, Plant et al. reported that radiation therapy successfully treated lung and paraspinal metastases in two patients. However, this analysis did not reveal a significant improvement in the OS of patients who received chemotherapy alone or radiation therapy. The lack of survival benefit with chemotherapy and radiation may be attributable to differences in patient populations. Patient receiving chemotherapy or radiation may have more advanced or aggressive disease. Unfortunately, information regarding disease extent is limited to tumor size and lymph node status.

The NCDB is a national database drawing on data centers from the entire United States. Accordingly, findings based on NCDB data may be more generalizable than findings based on data from a single institution. The limitations of this work include the retrospective nature of the data, the relatively limited sample size, and the lack of participation by many large independent children's hospitals in the NCDB. Also, staging of liver tumors according to Children's Oncology Group (COG) or pretreatment extent of disease (PRETEXT) staging was not available. No differentiation between the sequence of chemotherapy and surgical resection could be made, as these data were incomplete in many cases.

The data show that surgical resection is crucial and should be considered an integral part of treatment in children with UESL. Despite the absence of specific tumor staging information, outcomes in children is excellent with surgery or combined therapy. This offers valuable information for physicians in their discussions with patients and their families in regards to the proper treatment and prognosis for children with this rare liver tumor.

ACKNOWLEDGMENTS

The American College of Surgeons and American Cancer Society sponsored the National Cancer Database. The authors thank Ana Maria Rodriguez, PhD, a member of the Research Core Team at the Michael E. DeBakey Department of Surgery at Baylor, for her editorial assistance during the preparation of this manuscript. The authors also thank Courtney Arredondo, MSPH, a member of the Baylor College of Medicine Michael E. DeBakey Department of Surgery Research Core Team, for her assistance with statistical analysis during the preparation of this manuscript.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

1. Stocker JT, Ishak KG. Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases. Cancer. 1978;42:336–348.
2. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol. 1983;14(6):512–537.
3. Webber EM, Morrison KB, Pritchard SL, Sorensen PH. Undifferentiated embryonal sarcoma of the liver: results of clinical management in one center. J Pediatr Surg. 1999;34:1641–1644.
4. Pachera S, Nishio H, Takahashi Y, et al. Undifferentiated embryonal sarcoma of the liver: case report and literature survey. J Hepatobiliary Pancreat Surg. 2008;15:536–544.
5. Bisogno G, Pilz T, Perilongo G, et al. Undifferentiated sarcoma of the liver in childhood: a curable disease. Cancer. 2002;94:252–257.
6. Lenze F, Birkfellner T, Lenz P, et al. Undifferentiated embryonal sarcoma of the liver in adults. Cancer. 2008;112:2274–2282.
7. Wei ZG, Tang LF, Chen ZM, Tang HF, Li MJ. Childhood undifferentiated embryonal liver sarcoma: clinical features and immunohistochemistry analysis. J Pediatr Surg. 2008;43:1912–1919.
8. Joshi SW, Merchant NH, Jambhekar NA. Primary multilocular cystic undifferentiated (embryonal) sarcoma of the liver in childhood resembling hydatid cyst of the liver. Br J Radiol. 1997;70:314–316.
9. Buetow PC, Buck JL, Pantongrag-Brown L, et al. Undifferentiated (embryonal) sarcoma of the liver: pathologic basis of imaging findings in 28 cases. Radiology. 1997;203:779–783.
10. Chung EM, Lattin GE, Cube R, et al. From the archives of the AFIP: pediatric liver masses: radiologic-pathologic correlation part 2. Malignant tumors. Radiographics. 2011;31:483–507.
11. Nicol K, Savell V, Moore J, Teot L, Spunt SL, Qualman S. Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma: a Children's Oncology Group Study. Pediatr Dev Pathol. 2007;10:89–97.
12. Horowitz ME, Etubanabes E, Webber BL, et al. Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer. 1987;59:396–402.
13. Weitz J, Klimstra DS, Cymes K, et al. Management of primary liver sarcomas. Cancer. 2007;109:1391–1396.
14. Kim D-Y, Kim K-H, Jung S-E, Lee S-C, Park K-W, Kim W-K. Undifferentiated (embryonal) sarcoma of the liver: combination treatment by surgery and chemotherapy. J Pediatr Surg. 2002;37:1419–1423.
15. Almogly G, Lieberman S, Gips M, et al. Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol. 2004;30:421–427.
16. Uchiyama S, Imamura N, Hidaka H, et al. An unusual variant of a left paraduodenal hernia diagnosed and treated by laparoscopic surgery: report of a case. Surg Today. 2009;50:533–535.
17. Winchester DP, Stewart AK, Bura C, Scott Jones R. The National Cancer Database: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004;85:1–3.
18. Walker NI, Horn MJ, Strong RW, et al. Undifferentiated (embryonal) sarcoma of the liver. Pathologic findings and long-term survival after complete surgical resection. Cancer. 1992;69:52–59.
19. Lack EE, Schlou BL, Azumi N, et al. Undifferentiated (embryonal) sarcoma of the liver. Clinical and pathologic study of 16 cases with emphasis on immunohistochemical features. Am J Surg Pathol. 1991;15:1–16.
20. Techavichit P, Masand PM, Himes RW, et al. Undifferentiated embryonal sarcoma of the liver (UESL): a single-center experience and review of the literature. J Pediatr Hematol Oncol. 2016;38:261–268.
21. Walther A, Geller J, Coots A, et al. Multimodal therapy including liver transplantation for hepatic undifferentiated embryonal sarcoma: liver transplantation for the future. Liver Transpl. 2014;20:191–199.
22. Chen LE, Shepherd RW, Nadler ML, et al. Liver transplantation and chemotherapy in children with unresectable primary hepatic malignancies: development of a management algorithm. J Pediatr Gastroenterol. 2006;43:487–493.
23. Ismail H, Dembowska-Baginska B, Broniszczak D, et al. Treatment of undifferentiated embryonal sarcoma of the liver in children—single center experience. J Pediatr Surg. 2013;48:2202–2206.
24. Upadhyaya M, McKiernan P, Hobin D, et al. Primary hepatic sarcomas in children—a single-center experience over 19 years. J Pediatr Surg. 2010;45:2124–2128.

25. Cao Q, Ye Z, Chen S, Liu N, Li S, Liu F. Undifferentiated embryonal sarcoma of liver: a multi-institutional experience with 9 cases. Int J Clin Exp Pathol. 2014;7:8647–8656.

26. Leuschner I, Schmidt D, Harms D. Undifferentiated sarcoma of the liver in childhood: morphology, flow cytometry, and literature review. Hum Pathol. 1990;21:68–76.

27. Newman KD, Schisgall R, Reaman G, Guzzetta PC. Malignant mesenchymoma of the liver in children. J Pediatr Surg. 1989;24:781–783.

28. Urban CE, Mache CJ, Schwinger W, et al. Undifferentiated (embryonal) sarcoma of the liver in childhood. Successful combined-modality therapy in four patients. Cancer. 1993;72:2511–2516.

29. Baron PW, Majlessipour F, Bedros AA, et al. Undifferentiated embryonal sarcoma of the liver successfully treated with chemotherapy and liver resection. J Gastrointest Surg. 2007;11:73–75.

30. Kadomatsu K, Nakagawara A, Zaizen Y, et al. Undifferentiated (embryonal) sarcoma of the liver: report of three cases. Surg Today. 1992;22:451–455.

31. Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era—recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOP). Eur J Cancer. 2005;41:1031–1036.

32. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.

33. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2004;42:74–83.

34. Austin MT, Leys CM, Feurer ID, et al. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. J Pediatr Surg. 2006;41:182–186.

35. Plant AS, Busuttil RW, Rana A, et al. A single-institution retrospective cases series of childhood undifferentiated embryonal liver sarcoma (UELS): success of combined therapy and the use of orthotopic liver transplant. J Pediatr Hematol Oncol. 2013;35:451–455.

36. Okajima H, Ohya Y, Lee K-J, et al. Management of undifferentiated sarcoma of the liver including living donor liver transplantation as a backup procedure. J Pediatr Surg. 2009;44:e33–e38.

37. Kelly MJ, Martin L, Alonso M, Altura RA. Liver transplant for relapsed undifferentiated embryonal sarcoma in a young child. J Pediatr Surg. 2009;44:e1–e3.

38. Dower NA, Smith LJ, Lees G, et al. Experience with aggressive therapy in three children with unresectable malignant liver tumors. Med Pediatr Oncol. 2000;34:132–135.

39. McFadden DW, Kelley DJ, Sigmund DA, et al. Embryonal sarcoma of the liver in an adult treated with preoperative chemotherapy, radiation therapy, and hepatic lobectomy. Cancer. 1992;69:39–44.

40. Steiner M, Bostrum B, Leonard AS, Dehner LP. Undifferentiated (embryonal) sarcoma of the liver: A clinicopathologic study of a survivor treated with combined technique therapy. Cancer. 1998;64:1318–1322.